Literature DB >> 12118372

Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma.

Jin-Zhang Zeng1, Hong-Yang Wang, Zheng-Jun Chen, Axel Ullrich, Meng-Chao Wu.   

Abstract

To gain new insight into the molecular mechanism underlying the pathogenesis of human primary hepatocellular carcinoma (HCC), we searched for HCC-specific molecules through screening genes that are differentially expressed between cancerous and noncancerous counterparts of liver and identified a novel HCC-associated gene, HCCA1 encoding a approximately 80 kDa cytoplasmic protein that contains several proline-rich motifs likely for SH3-binding. HCCA1 transcript, albeit present in some adult tissues, is up-regulated selectively in HCC but not in other tumor cells. High expression of HCCA1 occurs as a late event frequently (89.2%) in HCCs and correlated significantly with the degree of tumor progression. When treated with antisense oligonucleotides to HCCA1, HCCA1 expression in HCC cells (HuH-7) was effectively suppressed and cell growth was down-regulated in a time- and dose-dependent manner. Furthermore, HuH-7 cells harboring the HCCA1 antisense expression clone displayed a remarkably reduced efficiency in colony formation. Together, these data strongly suggest that HCCA1 is a positive effector in cell proliferation and contributes to HCC carcinogenesis and progression. We believe that this protein will serve as a novel useful marker for HCC and is a potential target for pharmaceutical intervention of this malignant disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118372     DOI: 10.1038/sj.onc.1205652

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China.

Authors:  Ru-Lin Cai; Wei Meng; Hong-Yan Lu; Wen-Yao Lin; Feng Jiang; Fu-Min Shen
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

2.  ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line.

Authors:  Dustin Deming; Peter Geiger; Herbert Chen; Abram Vaccaro; Muthusamy Kunnimalaiyaan; Kyle Holen
Journal:  J Gastrointest Surg       Date:  2008-05       Impact factor: 3.452

3.  p42.3: a promising biomarker for the progression and prognosis of human colorectal cancer.

Authors:  Xiao-Sun Yuan; Yi Zhang; Xiao-Ya Guan; Bin Dong; Min Zhao; Lin-Lin Mao; You-Yong Lu; Xiu-Yun Tian; Chun-Yi Hao
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-11       Impact factor: 4.553

4.  Effect of Benzothiazole based conjugates in causing apoptosis by Regulating p53, PTEN and MAP Kinase proteins affecting miR-195a and miR-101-1.

Authors:  Sncvl Pushpavalli; M Janaki Ramaiah; Ch Srinivas; Debasmita Mukhopadhya; J L Aditya; Ravindra M Kumbhare; Utpal Bhadra; Manika Pal Bhadra
Journal:  Cancer Cell Int       Date:  2011-10-28       Impact factor: 5.722

5.  BC047440 antisense eukaryotic expression vectors inhibited HepG2 cell proliferation and suppressed xenograft tumorigenicity.

Authors:  Lu Zheng; Ping Liang; JianBo Zhou; XiaoBing Huang; Yu Wen; Zheng Wang; Jing Li
Journal:  Braz J Med Biol Res       Date:  2012-01-12       Impact factor: 2.590

6.  Differential expression of p42.3 in low- and high-grade gliomas.

Authors:  Weiqing Wan; Xiaoqing Xu; Guijun Jia; Wenmei Li; Junmei Wang; Tong Ren; Zhen Wu; Junting Zhang; Liwei Zhang; Youyong Lu
Journal:  World J Surg Oncol       Date:  2014-06-14       Impact factor: 2.754

7.  Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis.

Authors:  Hung Huynh; Thi Thanh Tuyen Nguyen; Kah-Hoe Pierce Chow; Puay Hoon Tan; Khee Chee Soo; Evelyne Tran
Journal:  BMC Gastroenterol       Date:  2003-08-08       Impact factor: 3.067

8.  Bioinformatics analysis of hepatitis C virus genotype 2a-induced human hepatocellular carcinoma in Huh7 cells.

Authors:  Ping Xu; Meiying Wu; Hui Chen; Junchi Xu; Minjuan Wu; Ming Li; Feng Qian; Junhua Xu
Journal:  Onco Targets Ther       Date:  2016-01-08       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.